Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia. (23rd July 2020)

• Record Type: Journal Article
• Authors: Boccia, Ralph; Cooper, Nichola; Ghanima, Waleed; Boxer, Michael A; Hill, Quentin A.; Sholzberg, Michelle; Tarantino, Michael D.; Todd, Leslie K.; Tong, Sandra; Bussel, James B.
• Is Part Of: British journal of haematology. Volume 190:Number 6(2020)
• Page Start: 933
• Page End: 938
• Publication Date: 2020-07-23
• Subjects: autoimmune -- platelet -- spleen tyrosine kinase -- SYK -- idiopathic thrombocytopenic purpura; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16959
• Languages: English
• ISSNs: 0007-1048

Abstract

Abstract: Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line therapy (after ≥2 prior lines of therapy including a second‐line agent). Platelet responses ≥50 000/µl were observed in 25/32 (78%) second‐line and 54/113 (48%) third‐or‐later‐line patients. Bleeding events were less frequent in second‐line (28%) versus third‐or‐later‐line (45%) patients. Responses once achieved tended to be durable in both groups. The safety profile was similar in both groups. In this post hoc analysis, fostamatinib was more effective as second‐line than third‐or‐later‐line therapy for ITP.